Live Markets
Wednesday, July 29, 2026·George Town, KY·29°·Partly Cloudy
Markets Open · NYSE·Newsletter·Masthead·
VOL. XII · NO. 117Established MMXIV · George Town, Grand CaymanAtlantic Edition · $4.50

The Cayman Journal

Finance · Business · Technology · Caribbean & Global Affairs
Markets · Healthcare

Alpha Teknova, Inc. (TKNO)

NGM · Drug Manufacturers - Specialty & Generic

$5.09+0.24 (+4.95%)Quote refreshed

Sources: Yahoo Finance (quote, statistics) · SEC EDGAR (filings, insider trades, 13F holders) · company filings & press wires

Market Cap
$272.9M
P/E (TTM)
EPS
$-0.33
Div Yield
52W Range
$1.91–$6.68
Beta
0.63

Company overview

Next earnings: 2026-08-05(8d)

Alpha Teknova, Inc. produces critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics in the United States and internationally. The company' primary products include pre-poured media plates for cell growth and cloning; liquid microbial culture media and supplements for cellular expansion; and molecular biology reagents for sample manipulation, resuspension, and purification. It provides lab essentials which provides chemical formulations for use in biological research and drug discovery; and clinical solutions, a custom product used in the development and production of protein therapies, gene therapies, mRNA vaccines, and diagnostic kits. The company serves its products to life sciences market, including pharmaceutical and biotechnology companies, contract development and manufacturing organizations, in vitro diagnostic franchises, as well as academic and government research institutions. Alpha Teknova, Inc. was founded in 1996 and is headquartered in Hollister, California.

Peers in Drug Manufacturers - Specialty & Generic

All in industry →

Recent press releases

April 2026

3 months agoDEF 14AHealthcare

TKNO annual proxy statement proposes electing directors and ratifying auditor

TKNOAlpha Teknova, Inc.

# 🗓️ What This Document Is 📄 This is Alpha Teknova, Inc.'s definitive Proxy Statement (DEF 14A) for the 2026 Annual Meeting of Stockholders. Think of this document as the company’s formal roadmap for its governance—it tells you exactly what decisions shareholders need to vote on, who is running t

Read summaryView on SEC EDGAR

SEC filings

All filings →
1 recent filing shown in the timeline above. View all SEC filings →

Alpha Teknova, Inc. has no reported insider trades in the last 90 days.

Institutional holders

All holders →
As of 2025-12-31 · prior 2025-09-30
737,265 sh-50.9%
593,100 sh-5.2%
730,912 sh+5.3%
200,000 sh-50.0%
998,532 sh+19.8%
293,576 sh● NEW
48,803 sh-68.8%

People at Alpha Teknova, Inc.

All people →

Quarterly financials

Full financials →
Revenue trend
03/25
$523.0K
NI -$4.6M
06/25
$7.8M
NI -$3.6M
09/25
$10.5M
NI -$4.3M
RevenueNI = Net Income
EPS trend (diluted)
Latest: $-0.08
Prior: $-0.07
Revenue sparkline